The impact of different IPV-OPV sequential immunization programs on hepatitis A and hepatitis B vaccine efficacy

Shiyi Chen, Yuping Zhao, Zhiyao Yang, Ying Li, Hongyuan Shi, Ting Zhao, Xiaolei Yang, Jing Li, Guoliang Li, Jianfeng Wang, Zhifang Ying, Jingsi Yang, Shiyi Chen, Yuping Zhao, Zhiyao Yang, Ying Li, Hongyuan Shi, Ting Zhao, Xiaolei Yang, Jing Li, Guoliang Li, Jianfeng Wang, Zhifang Ying, Jingsi Yang

Abstract

In recent years, the Global Polio Eradication Initiative has gradually implemented a global shift in polio immunization programs. Few studies cover polio immunization program impacts on the efficacy of other vaccines. This study investigated whether polio immunization programs affected hepatitis A (HepA) and hepatitis B (HepB) vaccination efficacy. Serum samples were collected from 968 infants before the first dose of polio vaccine, 28 days after completing primary polio immunization, and at 24 months old. Infants were classified into six polio immunization program groups: 1sIPV+2bOPV, 2sIPV+1bOPV, 2sIPV+1tOPV, 1cIPV+2bOPV, 2cIPV+1bOPV, and 2cIPV+1tOPV (sIPV: Sabin inactivated poliovirus vaccine; cIPV: Salk inactivated poliovirus vaccine; b, bivalent; t, trivalent; OPV, oral polio vaccine). No significant differences existed in antibody titers against HepA virus (anti-HAV) among the polio immunization program groups at any of the three time points (pre-first dose [p = 0.412], 28 days after primary immunization [p = 0.676], 24 months old [p = 0.556]). Before the first dose (p = 0.178) and at age 24 months (p = 0.987), no significant differences existed in HepB surface antibody (HBsAb) titers between the six polio immunization program groups). Twenty-eight days after primary immunization, no significant difference existed in HBsAb titers between groups after Bonferroni correction. Following HepA and HepB immunization, anti-HAV and HBsAb positivity reached > 98% in all groups, reflecting effective immunization. Our data suggest that different polio immunization programs did not affect HepA and HepB vaccine efficacy; HepA and HepB vaccines maintained high effectiveness irrespective of polio immunization program. This trial was registered on Clinical Trials.gov: NCT03614702.

Keywords: Inactivated poliovirus vaccines; hepatitis A virus; hepatitis B virus; oral poliovirus vaccines; sequential vaccination program; vaccination.

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Vaccination procedures used in this study.

References

    1. Bandyopadhyay AS, Garon J, Seib K, Orenstein WA.. Polio vaccination: past, present and future. Future Microbiol. 2015;10:791–6. PMID: 25824845. doi:10.2217/fmb.15.19.
    1. Global Polio Eradication Initiative . Two out of three wild poliovirus strains eradicated. Global Polio Eradication Initiative, World Health Organization, Geneva, Switzerland. 2019
    1. Ghendon Y, Robertson SE. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull World Health Organ. 1994;72:973–83. PMID: 7867144.
    1. Patel M, Zipursky S, Orenstein W, Garon J, Zaffran M. Polio endgame: the global introduction of inactivated polio vaccine. Expert Rev Vaccines. 2015;14:749–62. PMID: 25597843. doi:10.1586/14760584.2015.1001750.
    1. Hampton LM, Farrell M, Ramirez-Gonzalez A, Menning L, Shendale S, Lewis I, Rubin J, Garon J, Harris J, Hyde T, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:934–38. PMID: 27606675. doi:10.15585/mmwr.mm6535a3.
    1. World Health Organization . Meeting of the strategic advisory group of experts on immunization, November 2012 – conclusions and recommendations. Wkly Epidemiol Rec. 2013; 88:1–16. PMID: 23311010.
    1. World Health Organization . Guidelines for the safe production and quality control of inactivated poliomyelitis vaccine manufactured from wild polioviruses. Addendum to the Recommendations for the production and quality control of poliomyelitis vaccine (inactivated) WHO Technical Report Series, 2004, Annex. 2003.
    1. China; NHaFPCotPsRo . Immunization schedules and instructions for vaccines of the national immunization program(2016 Version). Chin J Viral Dis. 2017;7(2):81–86. PMID: 27279955. doi:10.11604/pamj.2016.23.128.8756.
    1. Luo J, Wang X, Ma F, Kang G, Ding Z, Ye C, Pan Y, Zhao Y, Hong S, Chen J, et al. Long-term immunogenicity and immune persistence of live attenuated and inactivated hepatitis a vaccines: a report on additional observations from a phase IV study. Clin Microbiol Infect. 2019;25:1422–27. PMID: 30496870. doi:10.1016/j.cmi.2018.11.005.
    1. Fangcheng Z, Xuanyi W, Mingding C, Liming J, Jie W, Qi J, Yuanping G, Wen Q, Yajuan X, Jiangsen M, et al. Era of vaccination heralds a decline in incidence of hepatitis A in high-risk groups in China. Hepat Mon. 2012;12:100–05. PMID: 22509186. doi:10.5812/hepatmon.838.
    1. Zhang X, An J, Tu A, Liang X, Cui F, Zheng H, Tang Y, Liu J, Wang X, Zhang N, et al. Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose. Hum Vaccin Immunother. 2016;12:2322–26. PMID: 27494260. doi:10.1080/21645515.2015.1134069.
    1. Bhave S, Sapru A, Bavdekar A, Kapatkar V, Mane A. Long-term immunogenicity of single dose of live attenuated hepatitis A vaccine in Indian children. Indian Pediatr. 2015;52:687–90. PMID: 26388627. doi:10.1007/s13312-015-0697-8.
    1. Lemon SM. Immunologic approaches to assessing the response to inactivated hepatitis A vaccine. J Hepatol. 1993;18(Suppl 2):S15–S19. PMID: 8182266. doi:10.1016/s0168-8278(05)80372-1.
    1. Song YJ, Lim J, Park WS, Sohn H, Lee MS, Shin DH, Kim CB, Kim H, Oh GJ, Ki M. Seropositivity among Korean Young Adults Approximately 2 years after a single-dose vaccination against Hepatitis A virus. PLoS One. 2015;10:e0142297. PMID: 26540392. doi:10.1371/journal.pone.0142297.
    1. Li J, Zhang ZJZ, Pan JB, Zhang HR, Li RQ, Li MZ, Lu L, Huang F, Wu J. Surveillance of immunization effectiveness and titer of type I and type III polio vaccine in Beijing before and after the adjustment of immunization strategy in 2012-2018. Zhonghua Yu Fang Yi Xue Za Zhi. 2020;54:779–83. doi:10.3760/cma.j.cn112150-20190621-00499.
    1. Ciapponi A, Bardach A, Rey Ares L, Glujovsky D, Cafferata ML, Cesaroni S, Bhatti A. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis. Cochrane Database Syst Rev. 2019;12:Cd011260. PMID: 31801180. doi:10.1002/14651858.CD011260.pub2.
    1. O’Ryan M, Bandyopadhyay AS, Villena R, Espinoza M, Novoa J, Weldon WC, Oberste MS, Self S, Borate BR, Asturias EJ, et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis. 2015;15:1273–82. PMID: 26318714. doi:10.1016/S1473-3099(15)00219-4.
    1. Asturias EJ, Bandyopadhyay AS, Self S, Rivera L, Saez-Llorens X, Lopez E, Melar M, Gaensbauer JT, Weldon WC, Oberste MS, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet. 2016;388:158–69. PMID: 27212429. doi:10.1016/S0140-6736(16)00703-0.
    1. Tang G, Yin W, Cao Y, Tan L, Wu S, Cao Y, Fu X, Yan J, Jiang X. Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: a systematic review and meta-analysis. Hum Vaccin Immunother. 2018;14:2636–43. PMID: 29985751. doi:10.1080/21645515.2018.1489188.
    1. Kanra G, Yalçin SS, Ceyhan M, Yurdakök K. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children. Turk J Pediatr. 2000;42:105–08. PMID: 10936974.
    1. Linder N, Karetnyi Y, Gidony Y, Ohel G, Levin E, Kuint J, Davidovich N, Gidony I, Mendelson E, Barzilai A. Placental transfer of hepatitis A antibodies in full term and preterm infants. Pediatr Infect Dis J. 1997;16:245–47. PMID: 9041609. doi:10.1097/00006454-199702000-00015.
    1. Linder N, Karetnyi Y, Gidony Y, Dagan R, Ohel G, Levin E, Mendelson E, Brazilai A. Decline of hepatitis A antibodies during the first 7 months of life in full-term and preterm infants. Infection. 1999;27:128–31. PMID: 10219645. doi:10.1007/BF02560513.
    1. López EL, Contrini MM, Xifró MC, Cattaneo MA, Zambrano B, Dumas R, Rouyrre N, Weber F. Hepatitis A vaccination of Argentinean infants: comparison of two vaccination schedules. Vaccine. 2007;25:102–08. PMID: 16914234. doi:10.1016/j.vaccine.2006.07.014.
    1. Liu XE, Wushouer F, Gou A, Kuerban M, Li X, Sun Y, Zhang J, Liu Y, J LI, Zhuang H. Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines: a single-blind, randomized, parallel-group clinical trial among children in Xinjiang Uighur Autonomous Region, China. Hum Vaccin Immunother. 2013;9:1460–65. PMID: 23571173. doi:10.4161/hv.24366.
    1. Wang Z, Zhang S, Luo C, Wu Q, Liu Q, Zhou YH, Hu Y. Transplacentally acquired maternal antibody against hepatitis B surface antigen in infants and its influence on the response to hepatitis B vaccine. PLoS One. 2011;6:e25130. PMID: 21966434. doi:10.1371/journal.pone.0025130.
    1. Roznovsky L, Orsagova I, Kloudova A, Tvrdik J, Kabieszova L, Lochman I, Mrazek J, Hozakova L, Zjevikova A, Pliskova L. Long-term protection against hepatitis B after newborn vaccination: 20-year follow-up. Infection. 2010;38:395–400. PMID: 20589522. doi:10.1007/s15010-010-0039-7.
    1. Chan PK, Ngai KL, Lao TT, Wong MC, Cheung T, Yeung AC, Chan MC, Luk SW. Response to booster doses of hepatitis B vaccine among young adults who had received neonatal vaccination. PLoS One. 2014;9:e107163. PMID: 25198289. doi:10.1371/journal.pone.0107163.
    1. Jing W, Liu J, Liu M. Eliminating mother-to-child transmission of HBV: progress and challenges in China. Front Med. 2020;14:21–29. PMID:31974872. doi:10.1007/s11684-020-0744-2.
    1. Zhao T, Mo Z, Ying Z, Huang T, Che Y, Li G, Yang X, Sun M, Jiang L, Shi L, et al. Post hoc analysis of two clinical trials to compare the immunogenicity and safety of different polio immunization schedules in Chinese infants. Ann Transl Med. 2021;9:253. PMID: 33708880. doi10.21037/atm-20-2537.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться